143 related articles for article (PubMed ID: 14709907)
1. Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes.
Niwa T; Shiraga T; Hashimoto T; Kagayama A
Biol Pharm Bull; 2004 Jan; 27(1):97-9. PubMed ID: 14709907
[TBL] [Abstract][Full Text] [Related]
2. Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes.
Niwa T; Shiraga T; Hashimoto T; Kagayama A
Biol Pharm Bull; 2004 Mar; 27(3):415-7. PubMed ID: 14993813
[TBL] [Abstract][Full Text] [Related]
3. Effect of probucol on cytochrome P450 activities in human liver microsomes.
Umehara K; Shimokawa Y; Miyamoto G
Biol Pharm Bull; 2002 Aug; 25(8):1112-4. PubMed ID: 12186421
[TBL] [Abstract][Full Text] [Related]
4. Effect of gamma-oryzanol on cytochrome P450 activities in human liver microsomes.
Umehara K; Shimokawa Y; Miyamoto G
Biol Pharm Bull; 2004 Jul; 27(7):1151-3. PubMed ID: 15256760
[TBL] [Abstract][Full Text] [Related]
5. No inhibition of cytochrome P450 activities in human liver microsomes by sulpiride, an antipsychotic drug.
Niwa T; Inoue S; Shiraga T; Takagi A
Biol Pharm Bull; 2005 Jan; 28(1):188-91. PubMed ID: 15635191
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine.
Umehara K; Shimokawa Y; Miyamoto G
Biol Pharm Bull; 2002 May; 25(5):682-5. PubMed ID: 12033517
[TBL] [Abstract][Full Text] [Related]
7. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
[TBL] [Abstract][Full Text] [Related]
8. Effects of etodolac on P450 isoform-specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Zinno A; Nonaka K; Mukai H
Arzneimittelforschung; 2005; 55(12):744-8. PubMed ID: 16430028
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.
Nakajima M; Ohyama K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Jul; 27(7):792-7. PubMed ID: 10383922
[TBL] [Abstract][Full Text] [Related]
10. Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes.
Niwa T; Yamamoto S; Saito M; Shiraga T; Takagi A
Yakugaku Zasshi; 2007 Jan; 127(1):209-16. PubMed ID: 17202802
[TBL] [Abstract][Full Text] [Related]
11. Effects of serotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes.
Niwa T; Yamamoto S; Saito M; Kobayashi N; Ikeda K; Noda Y; Takagi A
Biol Pharm Bull; 2006 Sep; 29(9):1931-5. PubMed ID: 16946512
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T
Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063
[TBL] [Abstract][Full Text] [Related]
13. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.
Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH
Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064
[TBL] [Abstract][Full Text] [Related]
14. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds.
Nakajima M; Suzuki M; Yamaji R; Takashina H; Shimada N; Yamazaki H; Yokoi T
Xenobiotica; 1999 Dec; 29(12):1191-202. PubMed ID: 10647906
[TBL] [Abstract][Full Text] [Related]
15. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.
Yoshimoto K; Echizen H; Chiba K; Tani M; Ishizaki T
Br J Clin Pharmacol; 1995 Apr; 39(4):421-31. PubMed ID: 7640150
[TBL] [Abstract][Full Text] [Related]
16. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
Eagling VA; Tjia JF; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
[TBL] [Abstract][Full Text] [Related]
17. A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4'-hydroxylation, chloroxazone 6-hydroxylation and testosterone 6beta-hydroxylation.
Easterbrook J; Fackett D; Li AP
Chem Biol Interact; 2001 May; 134(3):243-9. PubMed ID: 11336973
[TBL] [Abstract][Full Text] [Related]
18. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
19. Regional distribution of drug-metabolizing enzyme activities in the liver and small intestine of cynomolgus monkeys.
Nakanishi Y; Matsushita A; Matsuno K; Iwasaki K; Utoh M; Nakamura C; Uno Y
Drug Metab Pharmacokinet; 2011 Jun; 26(3):288-94. PubMed ID: 21273732
[TBL] [Abstract][Full Text] [Related]
20. Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.
Yang J; He MM; Niu W; Wrighton SA; Li L; Liu Y; Li C
Br J Clin Pharmacol; 2012 Feb; 73(2):268-84. PubMed ID: 21815912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
